<p>This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.</p>

This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.

Episode 497: Reflections on the capivasertib ODAC

Broadcasting the latest developments in GU cancer

Hosted by Brian Rini and Tom Powles 

Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center
Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Medicine

Health & Fitness

Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London

Share Episode 497: Reflections on the capivasertib ODAC

Sign up to save your podcasts

Episode 497: Reflections on the capivasertib ODAC

Episode 497: Reflections on the capivasertib ODAC

More shows like The Uromigos

TED Radio Hour

Freakonomics Radio

Planet Money

JAMA Clinical Reviews

Behind The Knife: The Surgery Podcast

Prostate Cancer Update

ASCO Daily News

The Diary Of A CEO with Steven Bartlett

OncLive® On Air

GU Cast | Urology Podcast

Oncology Today with Dr Neil Love

People I (Mostly) Admire

ZOE Science & Nutrition

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions